logo

For the Inventor, By the Inventor

Toronto, Canada

Arius Research, Inc.


USPTO Granted Patents = 33

% Expired Patents = 90.9

Forward Citations = 228

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal David S F Young (33 out of 44 patents)

silverMedal Susan E Hahn (28 out of 38 patents)

bronzeMedal Helen P Findlay (18 out of 27 patents)

4.  Lisa M Cechetto (8 out of 13 patents)

5.  Miyoko Takahashi (6 out of 9 patents)

6.  Alison L Ferry (4 out of 4 patents)

7.  Daad Sayegh (3 out of 6 patents)

8.  Luis A G Da Cruz (3 out of 3 patents)

9.  Fortunata McConkey (2 out of 5 patents)

10.  Luis A G daCruz (2 out of 3 patents)

11.  Shankar Kumar (1 out of 31 patents)

12.  Kristian Rogers (1 out of 1 patent)

13.  Michelle Kelleher (1 out of 2 patents)

14.  Andrea Warner (1 out of 1 patent)

15.  Paul Robert Hinton (1 out of 21 patents)


Core Competencies:
Antibody Therapy
Cancer Modifying Antibodies
Cytotoxicity
Surface Expression
MCSP
CD63
TROP-2
CD44
Individualized Antibodies
Patient-Specific Antibodies
Hepatocellular Carcinoma
Tumor Targeting

33 patents:

1. 7488475 - Antibody therapy of tumors (2009-02-10),
2. 7485300 - Cancerous disease modifying antibodies (2009-02-03),
3. 7468254 - Cytotoxicity mediation of cells evidencing surface expression of MCSP (2008-12-23),
4. 7456259 - Cancerous disease modifying antibodies (2008-11-25),
5. 7456258 - Cancerous disease modifying antibodies (2008-11-25),
6. 7456016 - Cancerous disease modifying antibodies (2008-11-25),
7. 7452979 - Cancerous disease modifying antibodies (2008-11-18),
8. 7452978 - Cancerous disease modifying antibodies (2008-11-18),
9. 7442777 - Cytotoxicity mediation of cells evidencing surface expression of CD63 (2008-10-28),
10. 7431923 - Cytotoxicity mediation of cells evidencing surface expression of CD63 (2008-10-07),
11. 7420041 - Cytotoxicity mediation of cells evidencing surface expression of TROP-2 (2008-09-02),
12. 7420040 - Cytotoxicity mediation of cells evidencing surface expression of TROP-2 (2008-09-02),
13. 7420039 - Individualized anti-cancer antibodies (2008-09-02),
14. 7419792 - Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody (2008-09-02),
15. 7411046 - Cancerous disease modifying antibodies (2008-08-12),
Company Overview
Arius Research, Inc. is a Toronto-based company specializing in advanced research and development in the field of biotechnology. The organization focuses on innovative solutions that enhance drug discovery and development processes, leveraging cutting-edge technologies to improve efficiency and outcomes in pharmaceutical research. With a commitment to scientific excellence, Arius Research collaborates with various stakeholders in the healthcare sector to drive advancements that address critical medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

33 Patents

#41 in Toronto

#405 in Canada

#20,130 in the World

Toronto, CA
Toronto, Canada

Arius Research, Inc.

Forward Citations = 228

15 inventors:

goldMedal David S F Young (33 out of 44 patents)

silverMedal Susan E Hahn (28 out of 38 patents)

bronzeMedal Helen P Findlay (18 out of 27 patents)

4.  Lisa M Cechetto (8 out of 13 patents)

5.  Miyoko Takahashi (6 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Arius Research, Inc.. Retrieved from https://idiyas.com/company/arius-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…